Skip to main content

Table 1 Patient and procedure characteristics

From: Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

 

N = 4,154*

%

Female

1,127

27.1

Age group (years)

  

<60

1,659

39.9

60-70

1,316

31.7

70+

1,179

28.4

Medication use†

  

Clopidogrel

3,931

94.6

Proton pump inhibitors

955

23.0

Aspirin

3,718

89.5

Vitamin K antagonists

301

7.2

Nonselective NSAIDs

509

12.3

COX-2 inhibitors

388

9.3

Oral glucocorticoids

309

7.4

Calcium channel blockers

1,153

27.8

Statins

3,606

86.8

Comorbidities‡

  

Diabetes

586

14.1

Hypertension

178

4.3

Year of study entry

  

2003

847

20.4

2004

1,836

44.2

2005

1,471

35.4

PCI Indication

  

STEMI

844

20.3

UAP/NSTEMI

1,277

30.7

SAP

1,902

45.8

Other

131

3.2

Number of treated arteries§

  

1

2,877

69.3

2

1,057

25.4

3

212

5.1

Number of Stents§

  

1

3,301

79.5

2

631

15.2

3+

208

5.0

Lesion Type§║

  

A

898

21.6

B

2,165

52.1

C

1,091

26.3

  1. *Drug-eluting stents only (n = 3,548) and combination of drug-eluting stents and bare metal stents (n = 606).
  2. †Any prescription redemption during follow up.
  3. ‡Registered between 1977 and the index PCI date.
  4. §Data were not available on number of treated arteries for 112 patients, on the number of stents for 62 patients, and on lesion type for 6 patients.
  5. ║Lesion classification: A = non-complicated, length <10 mm; B = irregular, length 10–20 mm; C = irregular, side branch, 90 degrees, chronic occlusion, length 20 mm.
  6. Abbreviations: COX cyclooxygenase, NSAIDs nonsteroidal anti-inflammatory drugs, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, SAP stable angina pectoris, UAP unstable angina pectoris, NSTEMI non-ST-segment elevation myocardial infarction.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us